You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Screen for hepatitis B virus in all cancer patients starting systemic treatment. Find out more about hepatitis B virus screening and management.

Drug Formulary
About the Drug Formulary Email Drug Formulary Team
Drug

Published Date: 01 Apr 2026

Revision Summary:
Drug Monograph: Removed NDFP funding information
Updated
Apr 2026
Drug

Published Date: 31 Mar 2026

Revision Summary:
Drug Monograph: New drug monograph
Patient Info Sheet EN: New drug information sheet
Patient Info Sheet FR: New information sheet (Nouvelle fiche d'information)
Updated
Mar 2026
Regimen
Published Date: 31 Mar 2026
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Revision Summary:

Regimen Monograph: Removed "Unfunded" info from bendamustine

Updated
Mar 2026
Regimen
Published Date: 31 Mar 2026
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Revision Summary:

Regimen Monograph: Modified Rationale/uses section; Removed bendamustine NDFP funding info

Updated
Mar 2026
Regimen
Published Date: 31 Mar 2026
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Revision Summary:

Regimen Monograph: Removed bortezomib NDFP funding info

Updated
Mar 2026
Regimen
Published Date: 31 Mar 2026
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Revision Summary:

Regimen Monograph: Removed bortezomib NDFP funding info

Updated
Mar 2026
Regimen
Published Date: 31 Mar 2026
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Revision Summary:

Regimen Monograph: Removed bortezomib NDFP funding info; Removed "unfunded" bortezomib status for cycles 5 and 6

Updated
Mar 2026
Regimen
Published Date: 31 Mar 2026
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Revision Summary:

Regimen Monograph: Removed bortezomib NDFP funding info; Removed "unfunded" bortezomib status for cycles 5 and 6

Updated
Mar 2026
Regimen
Published Date: 31 Mar 2026
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Revision Summary:
Regimen Monograph: Modified Rationale/uses section; Removed bortezomib NDFP funding info
Updated
Mar 2026
Regimen
Published Date: 31 Mar 2026
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Revision Summary:

Regimen Monograph: Removed bortezomib NDFP funding info

Updated
Mar 2026
Regimen
Published Date: 31 Mar 2026
Intent: Palliative
Revision Summary:

Regimen Monograph: Removed bortezomib NDFP funding info

Updated
Mar 2026
Regimen
Published Date: 31 Mar 2026
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Revision Summary:

Regimen Monograph: Removed bortezomib NDFP funding info

Updated
Mar 2026

Pages